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Introduction
Th  e European Network for Breast Development and 
Cancer (ENBDC) organized its second meeting to foster 
interactions and the sharing of protocols between groups 
working on breast development and cancer. Graduate 
students, postdocs and research associates were 
encouraged to attend. Th   e meeting included discussions 
on genomics, bioinformatics, intravital microscopy, 
disseminated tumor cells, ex vivo culture and in vivo 
models for studying breast cancer.
Bioinformatics/genomics (Chair: Matthew Smalley)
Nuno Barbosa-Morais (Cancer Research UK, Cambridge 
Research Institute) discussed the importance of the 
correct annotation of microarray probes and of being 
sure that a probe truly maps to the gene of interest. 
Further problems to consider are probes that map to 
intron-exon boundaries, the presence of SNPs, and 
alternative splicing, which, as is becoming apparent, 
occurs on a far wider scale than previously appreciated. 
Splicing may lead to diﬃ   culties when summarizing data 
from multiple probes apparently mapping to the same 
gene but which in fact detect diﬀ  erent splice variants. 
Overall, it is clear that whatever array platform is being 
used, application of the latest, most reliable annotation is 
important. In a test of annotation reliability, it was found 
that Refseq annotations are a more reliable guide to 
probe identity than GenBank/UniGene.
Britta Weigelt (Cancer Research UK, London Research 
Institute) spoke on the design of gene expression 
microarray studies, which fall into three types. Th  e  ﬁ  rst, 
class comparison, is a supervised analysis to deﬁ  ne 
molecular diﬀ   erences between predeﬁ   ned groups. Th  e 
second, class prediction, is a supervised analysis where, 
after identifying the transcriptional diﬀ  erences between 
predeﬁ   ned groups, a genomic classiﬁ   er (signature) is 
deﬁ  ned to classify new samples. It has become clear that 
class prediction signatures mainly identify tumors with 
high proliferation, although they do perform well in 
identifying poor prognosis tumors of the estrogen 
receptor-positive type. Th  e third, class discovery, is an 
unbiased approach based either on unsupervised hier-
archical clustering or centroids (single sample predictors 
(SSPs)). Both need to be used with caution. Clusters can 
always be detected in datasets but that does not 
necessarily mean they are stable or reproducible. SSPs 
aim to identify molecular subtypes prospectively based 
on the correlation between the centroids (that is, mean 
expression proﬁ  les for each subtype) and the tumor gene 
expression patterns. However, only ‘basal-like’ breast 
cancers can be robustly identiﬁ  ed with SSPs, and for them 
to be introduced for routine diagnosis, the methodologies 
and deﬁ   nitions for identiﬁ   cation of the breast cancer 
molecular subtypes need to be standardized.
Ex vivo culture models (Chair: Marina Glukhova)
Mohamed Bentires-Alj from the Friedrich Miescher 
Institute in Basel spoke on ‘Ex vivo models for studying 
breast cancer’. He ﬁ  rst showed that some cell biological 
eﬀ  ects are seen in three-dimensional but not in mono-
layer cultures, which suggests that signaling events are 
integrated diﬀ  erently in these culture models. He then 
described how to grow MCF10A cells as three-dimensional 
Abstract
The second meeting of the European Network for 
Breast Development and Cancer (ENBDC) on ‘Methods 
in Mammary Gland Development and Cancer’ was held 
in April 2010 in Weggis, Switzerland. The focus was on 
genomics and bioinformatics, extracellular matrix and 
stroma-epithelial cell interactions, intravital imaging, 
the search for metastasis founder cells and mouse 
models of breast cancer.
© 2010 BioMed Central Ltd
Methods in Mammary Gland Development and 
Cancer: the second ENDBC meeting - intravital 
imaging, genomics, modeling and metastasis
John Stingl1, Matthew J Smalley2, Marina A Glukhova3 and Mohamed Bentires-Alj*4
MEETING REPORT
*Correspondence: Bentires@fmi.ch
4Friedrich Miescher Institute for Biomedical Research (FMI), Maulbeerstr. 66; 
CH-4058 Basel, Switzerland
Full list of author information is available at the end of the article
Stingl et al. Breast Cancer Research 2010, 12:311 
http://breast-cancer-research.com/content/12/5/311
© 2010 BioMed Central Ltdcultures in Matrigel and emphasized the importance of 
testing the lots of Matrigel that are suitable for MCF10A 
three-dimensional cultures, as MCF10A cells do not 
form growth-arrested acinus-like structures with some 
lots. Bentires-Alj’s group generated three-dimensional 
culture models that recapitulate features of breast cancer 
progression, including increased prolifera  tion, loss of 
polarity, decreased apoptosis, ﬁ  lling of the lumen and 
invasion of the basement membrane. Finally, he 
presented work from his lab on breast stem cell-niche 
interactions showing that three-dimensional co-cultures 
of human breast epithelial cells and stroma cells obtained 
from reduction mammoplasties in a deﬁ  ned  culture 
medium allow the retention of the diﬀ  erentiation  and 
proliferation potentials of breast stem/progenitor cells (S 
Duss, H Brinkhaus, and M Bentires-Alj, unpublished data).
Lone Ronnov-Jessen from the University of 
Copenhagen talked about ‘Epithelial-stromal interactions 
in the human breast’. Tumor cells are known to activate 
the stroma; however, the stroma in turn can signiﬁ  cantly 
alter gene expression in tumors cells. Comparing 
transcriptional proﬁ   les of breast tumor cells growing 
alone or in co-culture with activated breast ﬁ  broblasts, 
they isolated and characterized a new gene, EPSTI1 
(Epithelial stromal interaction 1). EPSTI1 was not 
expressed in normal breast, whilst 22 of 40 breast 
carcinomas stained positive with anti-EPSTI1 antibody 
and EPSTI1 expression correlated with a lower tumor 
diﬀ  erentiation. Remarkably, ectopic expression of EPSTI1 
in one human breast epithelial cell line increased 
tumorspheres-forming ability and induced epithelial-
mesenchymal transition, whereas knockdown of EPSTI1 
in another cell line had the opposite eﬀ  ect. Th  ese  ﬁ  ndings 
suggest an important role for EPSTI1 in the regulation of 
tumor cell properties [1].
Imaging and isolation of tumor cells 
(Chair: Mohamed Bentires-Alj)
Jacco van Rheenen from Hubrecht Institute in Utrecht 
presented his work on intravital imaging of invasion and 
metastasis of mammary carcinomas. Intravital micro  scopy 
allows dynamic visualization of cellular and signaling 
events in tumors at subcellular resolution and in living 
animals. Th  e cells are usually engineered to express 
ﬂ  uorescent proteins prior to transplantation in mice and, 
in some cases, a photo-switchable ﬂ  uorescent  protein 
that permits tracking of the cells. To image mammary 
tumors, they use a mammary imaging window placed on 
top of the mouse mammary gland and a two-photon 
microscope [2]. Armed with this powerful technology, 
the Van Rheenen group has started to unravel new 
properties of tumor cells. For example, when trying to 
identify which cells enter the blood stream during tumor 
progression, they found that cells in the tumor mass enter 
the blood with higher eﬃ   ciency than cells at the leading 
edge of the tumor and, thus, might be the cells that 
metastasize to the lung. Th  ese results warrant further 
investigations and may yield new insights into metastasis.
Christoph Klein from the University of Regensburg 
presented data on ‘Th  e search for metastasis founder 
cells’. Th  e linear progression model of breast cancer 
postulates that normal cells progress to a fully malignant 
state exclusively within the primary tumor, where they 
develop the ability to grow into metastases. However, this 
view has been challenged by studies that suggest parallel 
evolution of cancer cells in distant sites such that cancer 
cells acquire successive alterations after their spread [3]. 
Both scenarios, however, may occur in patients. Asking 
when dissemination starts, the Klein group used 
antibodies against the epithelial marker cytokeratin to 
identify disseminated tumor cells (DTCs) in the bone 
marrow. Remarkably, the presence of a single DTC in the 
bone marrow of a patient with cancer accurately predicts 
a high risk of developing metastases. Th  is suggests that 
the metastases founder cell is within the DTCs. Th  ey 
developed single-cell genomic analysis approaches to 
characterize and compare DTCs to primary tumors in 
humans and in animal models of cancer. Th   ey found that 
dissemination is often an early event and that cancer cells 
are not fully malignant at the time of dissemination and 
will not autonomously and immediately form metastases 
after homing to a distant site. Indeed, most of the genetic 
evolution of cancer cells seems to occur after dissemi-
nation. Th  ey also compared metastases to primary 
tumors from the same patient and found a high genomic 
divergence (up to 80%) between the dominant popula-
tions in the primary tumors and metastases, further 
arguing for parallel evolution of cancer cells. Th  ese 
ﬁ  ndings could have therapeutic relevance since patients 
are usually stratiﬁ  ed for therapy based on analysis of their 
primary tumor and the presence of metastases. However, 
this may be an inappropriate way to stratify patients 
because the targets of adjuvant therapy are DTCs and 
metastases. Th  e parallel evolution model indicates that 
patients should be stratiﬁ  ed for therapy by analysis of 
DTCs and metastases. Finally, the results of these studies 
suggest that we should re-evaluate some of the cancer 
research models, for example, cell lines of metastatic 
origin (which largely exclude genomic evolution at 
distant sites) and preclinical models (which usually rely 
on the eﬃ   cacy of drugs on primary tumors).
Mouse models (Chair: John Stingl)
    Jos Jonkers from the Netherlands Cancer Institute in 
Amsterdam spoke about ‘Generating and analyzing a 
transgenic mouse’. He discussed the pros and cons of 
modifying the mouse germline via transgenesis or via 
gene targeting in embryonic stem cells and emphasized 
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reproducing aspects of sporadic human cancer in mice. 
He next presented examples of regulated in vivo knock-
down using a tetracycline-inducible short hairpin RNA 
(shRNA) one-vector system [4]. In vivo knockdown of 
Bmi1 and EZH2 using this technology reproduces the 
phenotypes of the respective knockout mice. His group is 
also using this strategy to test the roles of Bmi1 and EZH2 
in tumor maintenance. Th   ey cross the K14cre;Brca1F/F;p53F/F 
and  K14cre;EcadF/F;p53F/F mouse mammary tumor 
models [5,6] to mice expressing inducible shRNAs 
targeting Bmi1 or EZH2. An important limitation of this 
approach is the time consuming and expensive 
generation of mice with several mutations. To overcome 
this, Jos Jonkers discussed a more ﬂ  exible approach for 
generating mouse models of cancer simultaneously 
carrying several mutations. Th   is relies on the derivation 
of female embryonic stem (ES) cells from pre-existing 
mouse models of cancer using 3i medium that eﬀ  ectively 
keeps ES cells in their ground state [7]. For example, they 
derived ES cells from the K14cre;Brca1F/F;p53F/F mice and 
introduced an RMCE (recombinase-mediated cassette 
exchange) cassette into the Rosa26 locus. Th  is allows 
them to introduce any cDNA or shRNA of interest 
directly into these ES cells and then to produce chimeric 
females that can be monitored for mammary tumor 
development. Th   is approach will facilitate the 
identiﬁ  cation of collaborating oncogenic pathways and 
the validation of therapeutic targets in breast cancer.
Pentao Liu from the Wellcome Trust Sanger Institute 
in Hinxton spoke on ‘Transposons and forward genetics’. 
Transposons are widely used for generating mutations in 
model organisms. PiggyBac (PB) has recently been shown 
to transpose in mammalian cells after simply co-trans-
fecting the transposon and transposase plasmids. Th  e  PB 
has several advantages over other DNA-transposition 
systems currently used in mice. First, PB transposition is 
very eﬃ   cient and can be used to deliver various genetic 
elements (for example, cDNAs and small interfering 
RNA) to cells, including mammary epithelial cells. 
Second, the PB transposon carrying mutagenic cassettes 
can be used to perform eﬃ     cient genetic screens in 
cultured cells or in the mouse. Th  ird, PB transposons 
inserted into the genome can be excised, almost always 
precisely, thus allowing mutant phenotypes to be 
reverted. Fourth, reagents of the PB transposition system 
are available to the research community.
Conclusion
In the same spirit as last year [8], the meeting was an 
excellent occasion for brainstorming, exchanging proto-
cols and starting new collaborations. Th  e  ENBDC 
network and annual meeting are now open to any lab in 
the world working on breast development and cancer. If 
you would like your lab to become a member of the 
ENBDC, please visit the ENBDC website [9]. Planning 
has already started for the 2011 meeting to be held in 
Weggis on April 29 to May 1, which will certainly prove 
as stimulating as in 2009 and 2010.
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